Find a Doctor

David T. Teachey, MD

Attending physician

Assistant professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

Abstracts

Brown VI, Sheen C, Ryan T, Hulitt, DiNardo L, Barrett D, Teachey DT, Grupp SA: The PIM-1 inhibitor SIG-1776 alone and in combination with the mTOR inhibitor rapamycin in efficacious in preclinical models of pre-B ALL. Blood 112: 1922, Nov 2008 Notes: ASH Annual Meeting

Teachey DT, Sheen C, Brown VI, Grupp SA: Targeting eIF4E with ribavirin demonstrates a potentially effective strategy against acute lymphoblastic leukemia (ALL). Pediatr Blood and Cancer on line (www.aspho.org): 1296, May 2008 Notes: American Society of Pediatric Hematology/Oncology Annual Meeting.

Teachey DT, Schwabe D, Bleesing J, Manno CS, Sullivan KS, Grupp SA: Sirolimus is a safe and effective treatment for patients with Autoimmune Lymphoproliferative Syndrome (ALPS). Pediatr Blood and Cancer on line (www.aspho.org): 1286, May 2008 Notes: American Society of Pediatric Hematology/Oncology Annual Meeting.

Seif AE, Manno CS, Grupp SA, Teachey DT: Testing patients with Evans syndrome for the Autoimmune Lymphoproliferative Syndrome (ALPS): Results of a large multi-institutional clinical trial. Pediatr Blood and Cancer on line (www.aspho.org): 1299, May 2008 Notes: American Society of Pediatric Hematology/Oncology Annual Meeting *Plenary platform presentation.

Rheingold SR, Sacks N, Chang YJ, Brown VI, Teachey DT, Lange BJ, Grupp SA: A phase I trial of sirolimus (rapamycin) in pediatric patients with relapsed/refractory leukemia. Blood 110: 2834, Nov 2007 Notes: ASH Annual Meeting

Teachey DT, Seif A, Hall J, Ryan T, Sheen C, Reid G, Chang Y, Brown V, Grupp SA: Notch inhibitors are a safe and effective treatment for autoimmune lymphoproliferative syndrome. Pediatr Blood and Cancer 48: 6317.1, May 2007 Notes: American Society of Pediatric Hematology Oncology Annual Meeting, Oral Platform Presentation.

Teachey DT, Reid G, Fish J, Sheen C, Ryan T, Hall J, Brown V, Grupp SA: mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Pediatr Blood and Cancer 48: 5725.4, May 2007 Notes: American Society of Pediatric Hematology Oncology Annual Meeting, Oral Platform Presentation.

Teachey DT, Brown V, Reid G, Fish J, Grupp SA: mTOR inhibitors are synergistic with methotrexate: an effective combination to both prevent post-HSCT relapse of ALL and prevent GVHD. Biol Blood Marrow Transplant 13: 58, Feb 2007 Notes: ASBMT Tandem Transplant Meeting, February 2007, Oral Platform Presentation

 

 

Books

Chapters

Teachey DT, Rheingold S, Bunin N. Germ cell tumors. In: Brodeur G, Manno C, editors. Requisites in pediatrics: hematology and oncology. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.

Teachey DT, Bunin N. Hematopoietic stem cell transplantation. In: Haelfer M, Chambers J, editors. Requisites in pediatrics: critical care medicine. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.

Teachey DT. Lymphoproliferative disorders, myelodysplastic syndromes, and myeloproliferative disorders. In: Lanzkowsky P, editor. Manual of pediatric hematology/oncology. 5th ed. St. Louis:Academic Press, Elsevier; 2010.

Teachey DT, Manno C. Hematologic manifestations of systemic disease. In: Brodeur G, Manno C, editors. Requisites in pediatrics: hematology and oncology. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.

Teachey DT. Pallor. In: Schwartz MW, Bell LM, editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008.

Teachey DT. Wilms Tumor. In: Schwartz WM, Bell LM Jr., editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008.

Teachey DT. Acute myelogenous leukemia. In: Schwartz WM, Bell LM Jr., editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008. 

Original Papers

2011

Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. Epub 2011 Aug 16. doi: 10.1038/leu.2011.199. Cited in PubMed: PMID 21844871. Read the abstract

Rothman JA, Das R, Teachey DT, Paessler ME, Nichols KE. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Pediatr Blood Cancer. Epub 2011 Jun 16. doi: 10.1002/pbc.23226. Cited in PubMed: PMID 21681935. Read the abstract

Sheen C, Vincent T, Barrett D, Horwitz EM, Hulitt J, Strong E. Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis. Br J Haematol. Epub 2011 May 9. doi: 10.1111/j.1365-2141.2011.08696.x. Cited in PubMed:PMID 21554258. No abstract available.

Teachey DT. Autoimmune lymphoproliferative syndrome: new approaches to diagnosis and management. Clin Adv Hematol Oncol. 2011 mar;9(3):233-5. Cited in PubMed: PMID 21475130. No abstract available.

2010 

Kinjyo I, Gordon SM, Intlekofer AM, Dowdell K, Mooney EC, Caricchio R, et al. Cutting edge: lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin. J Immumol. 2010 Dec 15;185(12):7151-5. Epub 2010 Nov 12. Cited in PubMed: PMID 21076068. Read the abstract

Teachey DT. Somatic ALPS: a FAScinating condition. Blood. 2010 Jun 24;115(25):5125-6. Cited in PubMed: PMID 20576815. No abstract available.

Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010 Oct 7;116(14):e35-40. Epub 2010 Jun 10. Cited in PubMed: PMID 20538792. Read the abstract

Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010 mar 18:115(11):2142-5. Epub 2010 Jan 12. Cited in PubMed: PMID 20068224. Read the article

Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Hematol. 2010 Jan;148(2): 205-16, 2010. Epub 2009 Nov 23. Cited in PubMed: PMID 19930184. Read the article

Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome (ALPS) in children with Evans syndrome: a multi-institutional study. Blood 2010 Mar;115(11): 2142-5. Epub 2010 Jan 12. Cited in PubMed: PMID 20068224. Read the article

2009

Teachey DT, Jubelirer T, Baluarte H, Wade A, Manno CS. Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. Pediatr. Blood Cancer 53(6): 1114-6. Cited in PubMed: PMID 19621445. Read the abstract

Teachey DT, Grupp SA, Brown VI. mTOR Inhibitors and their potential role for therapy in leukemia and other haematologic malignancies. Br. J. Haematol. 2009 Jun;145(5): 569-80. Epub 2009 Mar 16. Cited in PubMed: PMID 19344392. Read the article

Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, et al.  Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 12009 Apr;45(1): 101-6. Epub 2009 Feb 4. Read the article

Milone M, Fish JD, Carpenito C, Carroll R, Binder G, Teachey D, et al. Chimeric receptors containing CD137signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo. Mol Ther. 2009 Aug;17(8): 1453-64. Epub 2009 Apr 21. Cited in PubMed: PMID 19384291. Read the article

« Back to Previous Page
  • Print
  • Share

Contact Us